



ANTAROS  
MEDICAL



20 December 2016

## Antaros Medical and Almi Invest adds 3 million SEK in venture capital to Emeriti Pharma

**Emeriti Pharma, which is developing a new treatment for skin diseases, takes up two million in venture capital from Antaros Medical. The existing owner, Almi Invest, is also participating in the funding, which has a total value of three million SEK. Emeriti Pharma also announces that the company is currently conducting a Phase 1 study with its drug candidate.**

Emeriti's drug candidate EP0003 is a patented molecule that specifically inhibits a critical enzyme involved in the development of some important skin diseases. This is a new concept for the treatment of rosacea and psoriasis. The project is now conducting the first clinical Phase 1 study. Previous pre-clinical studies show that EP0003 is very potent, has suitable properties for administration to the skin and large safety margins.

*"We are very pleased that Antaros Medical AB enters as partner and that Almi Invest increases its engagement in the company. Their financial support will allow us to conduct the Phase 1 study in a good way and begin planning for the further development of EP0003." says Emeriti Pharma's CEO David Gustafsson.*

**Antaros Medical's CEO Johannes Hulthe** adds: *"With Emeriti Pharma entering clinical phase, we see a clear synergy between Antaros robust expertise in clinical drug development, and, further on, access to innovative methods and techniques for analysis of the effect of the drug, in this cases skin lesions following treatment. We are very proud to contribute to the further development of EP0003. "*

### **About Emeriti Pharma:**

Emeriti Pharma has its origins in research at AstraZeneca in Gothenburg. The four founders are chairman Björn Wallmark, President David Gustafsson and chemists Tomas Fex and Bengt Olsson. All of them have extensive research experience in the pharmaceutical industry. Emeriti Pharma has laboratories and offices in AstraZeneca BioVenture Hub located within the premises of AstraZeneca in Mölndal. The firm is coached by Sahlgrenska Science Park.

For further information contact: [david.gustafsson@emeritipharma.se](mailto:david.gustafsson@emeritipharma.se). Phone: 070-695 15:34

### **About Antaros Medical:**

Antaros Medical is an R&D company within the Life Science area. The company is pioneering new frontiers in innovative PET and MR imaging methods, leading to improved, evidence-based decision making in clinical drug development. The company is specialized in cardio-metabolic diseases and oncology. Antaros Medical has a global network of customer including both big and small drug developing companies.

Learn more at: [www.antarosmedical.com](http://www.antarosmedical.com)

For more information, please contact [johannes.hulthe@antarosmedical.com](mailto:johannes.hulthe@antarosmedical.com)

## FACTS: ROSACEA AND PSORIASIS

*Rosacea is a chronic inflammatory skin disease in the face with redness and sometimes acne-like lesions. Several underlying mechanisms are discussed. Patients often experience reduced quality of life.*

*Psoriasis is a chronic skin disease causing red spots, scaling and sometimes itching. The disease is considered to be autoimmune, i.e. the inflammatory cells attack the body's own structure. Mild forms, which most common, are treated locally.*